[English] 日本語
Yorodumi- PDB-8vyf: SARS-CoV-2 S NTD (C.37 Lambda variant) plus S2L20 and S2X303 Fabs... -
+Open data
-Basic information
Entry | Database: PDB / ID: 8vyf | ||||||
---|---|---|---|---|---|---|---|
Title | SARS-CoV-2 S NTD (C.37 Lambda variant) plus S2L20 and S2X303 Fabs, local refinement | ||||||
Components |
| ||||||
Keywords | VIRAL PROTEIN/IMMUNE SYSTEM / sars-cov-2 / coronavirus / lambda / s2l20 / s2x303 / C.37 / antibody / Fab / S protein / spike / fusion protein / Structural Genomics / Seattle Structural Genomics Center for Infectious Disease / SSGCID / VIRAL PROTEIN / VIRAL PROTEIN-IMMUNE SYSTEM complex | ||||||
Function / homology | Function and homology information Maturation of spike protein / viral translation / Translation of Structural Proteins / Virion Assembly and Release / host cell surface / host extracellular space / suppression by virus of host tetherin activity / Induction of Cell-Cell Fusion / structural constituent of virion / entry receptor-mediated virion attachment to host cell ...Maturation of spike protein / viral translation / Translation of Structural Proteins / Virion Assembly and Release / host cell surface / host extracellular space / suppression by virus of host tetherin activity / Induction of Cell-Cell Fusion / structural constituent of virion / entry receptor-mediated virion attachment to host cell / host cell endoplasmic reticulum-Golgi intermediate compartment membrane / receptor-mediated endocytosis of virus by host cell / Attachment and Entry / membrane fusion / positive regulation of viral entry into host cell / receptor-mediated virion attachment to host cell / receptor ligand activity / symbiont-mediated suppression of host innate immune response / host cell surface receptor binding / fusion of virus membrane with host plasma membrane / fusion of virus membrane with host endosome membrane / viral envelope / virion attachment to host cell / SARS-CoV-2 activates/modulates innate and adaptive immune responses / host cell plasma membrane / virion membrane / identical protein binding / membrane / plasma membrane Similarity search - Function | ||||||
Biological species | Severe acute respiratory syndrome coronavirus 2 Homo sapiens (human) | ||||||
Method | ELECTRON MICROSCOPY / single particle reconstruction / cryo EM / Resolution: 3.2 Å | ||||||
Authors | McCallum, M. / Veesler, D. / Seattle Structural Genomics Center for Infectious Disease (SSGCID) | ||||||
Funding support | United States, 1items
| ||||||
Citation | Journal: Nat Commun / Year: 2024 Title: Quantifying how single dose Ad26.COV2.S vaccine efficacy depends on Spike sequence features. Authors: Craig A Magaret / Li Li / Allan C deCamp / Morgane Rolland / Michal Juraska / Brian D Williamson / James Ludwig / Cindy Molitor / David Benkeser / Alex Luedtke / Brian Simpkins / Fei Heng / ...Authors: Craig A Magaret / Li Li / Allan C deCamp / Morgane Rolland / Michal Juraska / Brian D Williamson / James Ludwig / Cindy Molitor / David Benkeser / Alex Luedtke / Brian Simpkins / Fei Heng / Yanqing Sun / Lindsay N Carpp / Hongjun Bai / Bethany L Dearlove / Elena E Giorgi / Mandy Jongeneelen / Boerries Brandenburg / Matthew McCallum / John E Bowen / David Veesler / Jerald Sadoff / Glenda E Gray / Sanne Roels / An Vandebosch / Daniel J Stieh / Mathieu Le Gars / Johan Vingerhoets / Beatriz Grinsztejn / Paul A Goepfert / Leonardo Paiva de Sousa / Mayara Secco Torres Silva / Martin Casapia / Marcelo H Losso / Susan J Little / Aditya Gaur / Linda-Gail Bekker / Nigel Garrett / Carla Truyers / Ilse Van Dromme / Edith Swann / Mary A Marovich / Dean Follmann / Kathleen M Neuzil / Lawrence Corey / Alexander L Greninger / Pavitra Roychoudhury / Ollivier Hyrien / Peter B Gilbert / Abstract: In the ENSEMBLE randomized, placebo-controlled phase 3 trial (NCT04505722), estimated single-dose Ad26.COV2.S vaccine efficacy (VE) was 56% against moderate to severe-critical COVID-19. SARS-CoV-2 ...In the ENSEMBLE randomized, placebo-controlled phase 3 trial (NCT04505722), estimated single-dose Ad26.COV2.S vaccine efficacy (VE) was 56% against moderate to severe-critical COVID-19. SARS-CoV-2 Spike sequences were determined from 484 vaccine and 1,067 placebo recipients who acquired COVID-19. In this set of prespecified analyses, we show that in Latin America, VE was significantly lower against Lambda vs. Reference and against Lambda vs. non-Lambda [family-wise error rate (FWER) p < 0.05]. VE differed by residue match vs. mismatch to the vaccine-insert at 16 amino acid positions (4 FWER p < 0.05; 12 q-value ≤ 0.20); significantly decreased with physicochemical-weighted Hamming distance to the vaccine-strain sequence for Spike, receptor-binding domain, N-terminal domain, and S1 (FWER p < 0.001); differed (FWER ≤ 0.05) by distance to the vaccine strain measured by 9 antibody-epitope escape scores and 4 NTD neutralization-impacting features; and decreased (p = 0.011) with neutralization resistance level to vaccinee sera. VE against severe-critical COVID-19 was stable across most sequence features but lower against the most distant viruses. | ||||||
History |
|
-Structure visualization
Structure viewer | Molecule: MolmilJmol/JSmol |
---|
-Downloads & links
-Download
PDBx/mmCIF format | 8vyf.cif.gz | 168.8 KB | Display | PDBx/mmCIF format |
---|---|---|---|---|
PDB format | pdb8vyf.ent.gz | Display | PDB format | |
PDBx/mmJSON format | 8vyf.json.gz | Tree view | PDBx/mmJSON format | |
Others | Other downloads |
-Validation report
Summary document | 8vyf_validation.pdf.gz | 1.7 MB | Display | wwPDB validaton report |
---|---|---|---|---|
Full document | 8vyf_full_validation.pdf.gz | 1.7 MB | Display | |
Data in XML | 8vyf_validation.xml.gz | 37 KB | Display | |
Data in CIF | 8vyf_validation.cif.gz | 52.4 KB | Display | |
Arichive directory | https://data.pdbj.org/pub/pdb/validation_reports/vy/8vyf ftp://data.pdbj.org/pub/pdb/validation_reports/vy/8vyf | HTTPS FTP |
-Related structure data
Related structure data | 43659MC 8vyeC 8vygC C: citing same article (ref.) M: map data used to model this data |
---|---|
Similar structure data | Similarity search - Function & homologyF&H Search |
-Links
-Assembly
Deposited unit |
|
---|---|
1 |
|
-Components
-Protein , 1 types, 1 molecules A
#1: Protein | Mass: 140929.156 Da / Num. of mol.: 1 Source method: isolated from a genetically manipulated source Details: Lambda spike glycoprotein, NTD Source: (gene. exp.) Severe acute respiratory syndrome coronavirus 2 Gene: S, 2 / Production host: Homo sapiens (human) / References: UniProt: P0DTC2 |
---|
-Antibody , 4 types, 4 molecules BCHL
#2: Antibody | Mass: 13541.036 Da / Num. of mol.: 1 Source method: isolated from a genetically manipulated source Source: (gene. exp.) Homo sapiens (human) / Production host: Homo sapiens (human) |
---|---|
#3: Antibody | Mass: 11829.141 Da / Num. of mol.: 1 Source method: isolated from a genetically manipulated source Source: (gene. exp.) Homo sapiens (human) / Production host: Homo sapiens (human) |
#4: Antibody | Mass: 13737.725 Da / Num. of mol.: 1 Source method: isolated from a genetically manipulated source Source: (gene. exp.) Homo sapiens (human) / Production host: Homo sapiens (human) |
#5: Antibody | Mass: 11270.294 Da / Num. of mol.: 1 Source method: isolated from a genetically manipulated source Source: (gene. exp.) Homo sapiens (human) / Production host: Homo sapiens (human) |
-Sugars , 3 types, 8 molecules
#6: Polysaccharide | beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta- ...beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose Source method: isolated from a genetically manipulated source | ||
---|---|---|---|
#7: Polysaccharide | Source method: isolated from a genetically manipulated source #8: Sugar | ChemComp-NAG / |
-Details
Has ligand of interest | N |
---|
-Experimental details
-Experiment
Experiment | Method: ELECTRON MICROSCOPY |
---|---|
EM experiment | Aggregation state: PARTICLE / 3D reconstruction method: single particle reconstruction |
-Sample preparation
Component | Name: SARS-CoV-2 S C.37 (Lambda variant) plus S309, S2L20, and S2X303 Fabs. Local refinement of NTD with S2L20 and S2X303 Fabs. Type: COMPLEX / Entity ID: #1-#5 / Source: RECOMBINANT |
---|---|
Source (natural) | Organism: Severe acute respiratory syndrome coronavirus 2 |
Source (recombinant) | Organism: Homo sapiens (human) |
Buffer solution | pH: 8 |
Specimen | Embedding applied: NO / Shadowing applied: NO / Staining applied: NO / Vitrification applied: YES |
Vitrification | Cryogen name: ETHANE |
-Electron microscopy imaging
Experimental equipment | Model: Titan Krios / Image courtesy: FEI Company |
---|---|
Microscopy | Model: FEI TITAN KRIOS |
Electron gun | Electron source: FIELD EMISSION GUN / Accelerating voltage: 300 kV / Illumination mode: FLOOD BEAM |
Electron lens | Mode: BRIGHT FIELD / Nominal defocus max: 30000 nm / Nominal defocus min: 2000 nm |
Image recording | Electron dose: 63 e/Å2 / Film or detector model: GATAN K3 (6k x 4k) |
-Processing
CTF correction | Type: PHASE FLIPPING AND AMPLITUDE CORRECTION |
---|---|
3D reconstruction | Resolution: 3.2 Å / Resolution method: FSC 0.143 CUT-OFF / Num. of particles: 95557 / Symmetry type: POINT |